Twelve-year trend in treatment seeking for buprenorphine abuse in Finland

Drug and Alcohol Dependence

Volumn 127, Issue 1-3, 2013, Pages 207-214

  Uosukainen, Hanna ^a   Kauhanen, Jussi ^a   Voutilainen, Sari ^a   Föhr, Jaana ^b   Paasolainen, Mika ^b   Tiihonen, Jari ^a,c,d   Laitinen, Kirsti ^a   Onyeka, Ifeoma N ^a   Bell, J Simon ^a,e  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Helsinki Deaconess Institute   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Amphetamine; Buprenorphine; Epidemiologic methods; Heroin; Substance abuse; Treatment seeking

Indexed keywords

ALCOHOL; CANNABIS; CENTRAL STIMULANT AGENT;

ADULT; AGE; ALCOHOL ABUSE; AMPHETAMINE ABUSE; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DRUG ABUSE; DRUG USE; ETHNIC GROUP; FEMALE; FINLAND; FINNISH; HELP SEEKING BEHAVIOR; HEROIN DEPENDENCE; HIGH RISK PATIENT; HOMELESSNESS; HUMAN; INTRAVENOUS ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NARCOTIC DEPENDENCE; ONSET AGE; PRESCRIPTION; PRIORITY JOURNAL; SELF REPORT; SEX; STRUCTURED INTERVIEW; TREND STUDY;

ADULT; BUPRENORPHINE; FEMALE; FINLAND; HUMANS; MALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; QUESTIONNAIRES; SELF REPORT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870922935     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.07.002     Document Type: Article

References (66)

1. Aich T.K., Dhungana M., Khanal R. Pattern of buprenorphine abuse among opioid abusers in Nepal. Indian J. Psychiatry 2010, 52:250-253.
2. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007, 88:75-78.
3. Basu D., Mattoo S.K., Malhotra A., Gupta N., Malhotra R. A longitudinal study of male buprenorphine addicts attending an addiction clinic in India. Addiction 2000, 95:1363-1372.
4. Bazazi A.R., Yokell M., Fu J.J., Rich J.D., Zaller N.D. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J. Addict. Med. 2011, 5:175-180.
5. Blacken P., Hendriks V., Pozzi G., Tempesta E., Hartgers C., Koeter M., Fahrner E.M., Gsellhofer B., Küfner H., Kokkevi A., Uchtenhagen A. European Addiction Severity Index (EuropASI). A Guide to Training and Administering EuropASI Interviews 1994, Available from: http://www.emcdda.europa.eu/html.cfm/index3647EN.html (accessed 27.07.11).
6. Bohnert A.S., Valenstein M., Bair M.J., Ganoczy D., McCarthy J.F., Ilgen M.A., Blow F.C. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011, 305:1315-1321.
7. Brands B., Blake J., Sproule B., Gourlay D., Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004, 73:199-207.
8. Brecht M.L., O'Brien A., von Mayrhauser C., Anglin M.D. Methamphetamine use behaviors and gender differences. Addict. Behav. 2004, 29:89-106.
9. Bruce R.D., Govindasamy S., Sylla L., Kamarulzaman A., Altice F.L. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am. J. Drug Alcohol Abuse 2009, 35:68-72.
10. Chowdhury A.N., Chowdhury S. Buprenorphine abuse: report from India. Br. J. Addict. 1990, 85:1349-1350.
11. Cicero T.J., Inciardi J.A., Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J. Pain 2005, 6:662-672.
12. Cicero T.J., Surratt H.L., Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J. Opioid Manag. 2007, 3:302-308.
13. Coben J.H., Davis S.M., Furbee P.M., Sikora R.D., Tillotson R.D., Bossarte R.M. Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am. J. Prev. Med. 2010, 38:517-524.
14. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006, 81:103-107.
15. Daniulaityte R., Falck R., Carlson R.G. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Depend. 2011, 122:201-207.
16. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998, 51:253-263.
17. Darke S., Hall W. Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend. 1995, 39:231-235.
18. Degenhardt L., Larance B., Mathers B., Azim T., Kamarulzaman A., Mattick R., Panda S., Toufik A., Tyndall M., Wiessing L., Wodak A. Benefits and Risks of Pharmaceutical Opioids: Essential Treatment and Diverted Medication. A Global Review of Availability, Extra-Medical Use, Injection and the Association with HIV 2008, Available from: http://www.unodc.org/documents/hiv-aids/publications/Benefits_and_risks_of_pharmaceutical_opioids.pdf (accessed 22.08.11).
19. Degenhardt L., Larance B.K., Bell J.R., Winstock A.R., Lintzeris N., Ali R.L., Scheuer N., Mattick R.P. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med. J. Aust. 2009, 191:161-165.
20. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2000. Treatment Demand Indicator, Standard Protocol 2.0. EMCDDA Scientific Report, Lisbon.
21. Fischer B., Patra J., Cruz M.F., Gittins J., Rehm J. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug Alcohol Rev. 2008, 27:625-632.
22. Fischer B., Rehm J., Patra J., Cruz M.F. Changes in illicit opioid use across Canada. CMAJ 2006, 175:1385-1387.
23. Forsell, M., Virtanen, A., Jääskeläinen, M., Alho, H., Partanen, A., 2010. Drug Situation in Finland 2010. National report to the EMCDDA by the Finnish National Focal Point, National Institute for Health and Welfare (THL), Report 39/2010.
24. Gossop M., Griffiths P., Powis B., Strang J. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br. J. Addict. 1992, 87:1527-1536.
25. Hakansson A., Medvedeo A., Andersson M., Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur. Addict. Res. 2007, 13:207-215.
26. Hakkarainen P., Tigerstedt C. Korvaushoidon läpimurto Suomessa (the breakthrough of Finnish substitution treatment). Yhteiskuntapolitiikka 2005, 70:143-154. (abstract in English).
27. Häkkinen M., Launiainen T., Vuori E., Ojanperä I. Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur. J. Clin. Pharmacol. 2012, 68:301-309.
28. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 1978, 35:501-516.
29. Johanson C.E., Arfken C.L., di Menza S., Schuster C.R. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012, 120:190-195.
30. Kaye S., Darke S. A comparison of the harms associated with the injection of heroin and amphetamines. Drug Alcohol Depend. 2000, 58:189-195.
31. Kumar M.S., Mudaliar S., Thyagarajan S.P., Kumar S., Selvanayagam A., Daniels D. Rapid assessment and response to injecting drug use in Madras, south India. Int. J. Drug Policy 2000, 11:83-98.
32. Lankenau S.E., Teti M., Silva K., Jackson Bloom J., Harocopos A., Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int. J. Drug Policy 2012, 23:37-44.
33. Larance B., Ambekar A., Azim T., Murthy P., Panda S., Degenhardt L., Mathers B. The availability, diversion and injection of pharmaceutical opioids in South Asia. Drug Alcohol Rev. 2011, 30:246-254.
34. Larance B., Degenhardt L., Lintzeris N., Bell J., Winstock A., Dietze P., Mattick R., Ali R., Horyniak D. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug Alcohol Depend. 2011, 118:265-273.
35. Lavelle T.L., Hammersley R., Forsyth A. The use of buprenorphine and temazepam by drug injectors. J. Addict. Dis. 1991, 10:5-14.
36. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197:517-532.
37. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J. Nerv. Ment. Dis. 1980, 168:26-33.
38. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., Schottenfeld R.S. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J. Gen. Intern. Med. 2007, 22:527-530.
39. Moratti E., Kashanpour H., Lombardelli T., Maisto M. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy. Clin. Drug Investig. 2010, 30(Suppl. 1):S3-S11.
40. Napper L.E., Fisher D.G., Johnson M.E., Wood M.M. The reliability and validity of drug users' self reports of amphetamine use among primarily heroin and cocaine users. Addict. Behav. 2010, 35:350-354.
41. Nielsen S., Bruno R., Lintzeris N., Fischer J., Carruthers S., Stoove M. Pharmaceutical opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia?. Drug Alcohol Rev. 2011, 30:291-299.
42. Nielsen S., Dietze P., Lee N., Dunlop A., Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007, 102:616-622.
43. O'Connor J.J., Moloney E., Travers R., Campbell A. Buprenorphine abuse among opiate addicts. Br. J. Addict. 1988, 83:1085-1087.
44. Office of Applied Studies (OAS), 2010. Treatment Episode Data Set (TEDS) 1998-2008: National Admissions to Substance Abuse Treatment Services. DASIS Series: S-50. HHS Publication No. (SMA) 09-4471, Rockville, MD. Substance Abuse and Mental Health Services Administration.
45. Office of National Drug Control Policy Epidemic: Responding to America's Prescription Drug Abuse Crisis 2011, Available from: http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf (accessed 23.08.11).
46. Otiashvili D., Zabransky T., Kirtadze I., Piralishvili G., Chavchanidze M., Miovsky M. Why do the clients of Georgian needle exchange programmes inject buprenorphine?. Eur. Addict. Res. 2010, 16:1-8.
47. Partanen A., Holmström P., Holopainen A., Perälä R. Buprenorfiinin pistäminen yleistynyt huumeiden sekakäytössä. Finn. Med. J. 2004, 59:3605-3611. (abstract in English).
48. Partanen P., Hakkarainen P., Hankilanoja A., Kuussaari K., Rönkä S., Salminen M., Seppälä T., Virtanen A. Amfetamiinien ja opiaattien ongelmakäytön yleisyys Suomessa 2005. Yhteiskuntapolitiikka 2007, 72:553-561. (in Finnish).
49. Partanen P., Hakkarainen P., Holmström P., Kinnunen A., Lammi R., Leinikki P., Partanen A., Seppälä T., Simpura J., Virtanen A. Amfetamiinien ja opiaattien käytön yleisyys Suomessa 1998. Yhteiskuntapolitiikka 2000, 65:534-541. (in Finnish).
50. Robinson G.M., Dukes P.D., Robinson B.J., Cooke R.R., Mahoney G.N. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington New Zealand. Drug Alcohol Depend. 1993, 33:81-86.
51. Rosenblum A., Parrino M., Schnoll S.H., Fong C., Maxwell C., Cleland C.M., Magura S., Haddox J.D. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007, 90:64-71.
52. Roux P., Villes V., Blanche J., Bry D., Spire B., Feroni I., Carrieri M.P. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend. 2008, 97:105-113.
53. Schuman-Olivier Z., Albanese M., Nelson S.E., Roland L., Puopolo F., Klinker L., Shaffer H.J. Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. J. Subst. Abuse Treat. 2010, 39:41-50.
54. Sigmon S.C. Characterizing the emerging population of prescription opioid abusers. Am. J. Addict. 2006, 15:208-212.
55. Simon R., Donmall M., Hartnoll R., Kokkevi A., Ouwehand A.W., Stauffacher M., Vicente J. The EMCDDA/Pompidou Group treatment demand indicator protocol: a European core item set for treatment monitoring and reporting. Eur. Addict. Res. 1999, 5:197-207.
56. Simon S.L., Richardson K., Dacey J., Glynn S., Domier C.P., Rawson R.A., Ling W. A comparison of patterns of methamphetamine and cocaine use. J. Addict. Dis. 2002, 21:35-44.
57. Subramaniam G.A., Stitzer M.A. Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder. Drug Alcohol Depend. 2009, 101:13-19.
58. Substance Abuse and Mental Health Services Administration, 2009. Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication no SMA 09-4434, Table G2), Rockville, MD.
59. Talu A., Rajaleid K., Abel-Ollo K., Ruutel K., Rahu M., Rhodes T., Platt L., Bobrova N., Uuskula A. HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn Estonia: implications for intervention. Int. J. Drug Policy 2010, 21:56-63.
60. Vicknasingam B., Mazlan M., Schottenfeld R.S., Chawarski M.C. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend. 2010, 111:44-49.
61. Vidal-Trecan G., Varescon I., Nabet N., Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003, 69:175-181.
62. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 1994, 55:569-580.
63. Winslow M., Ng W.L., Mythily S., Song G., Yiong H.C. Socio-demographic profile and help-seeking behaviour of buprenorphine abusers in Singapore. Ann. Acad. Med. Singapore 2006, 35:451-456.
64. World Health Organization Lexicon of Alcohol and Drug Terms 2012, Available from: http://www.who.int/substance_abuse/terminology/who_lexicon/en/print.html (accessed 16.05.12).
65. Wu L.T., Woody G.E., Yang C., Mannelli P., Blazer D.G. Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Subst. Abuse Rehabil. 2011, 2011:77-88.
66. Yokell M.A., Zaller N.D., Green T.C., Rich J.D. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr. Drug Abuse Rev. 2011, 4:28-41.